Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Barchart on MSN4h
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?
Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
Medical Marketing & Media10h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The ‘Ozempic Dupes’ Are Coming, and They Might Work Even Better
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...